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Aldosterone secretion in patients with 
septic shock: a prospective study
Secreção de aldosterona em pacientes com 
choque séptico: estudo prospectivo
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ABSTRACT
Objective: To assess serum levels of the main factors that regulate the activation of the zona 
glomerulosa and aldosterone production in patients with septic shock, as well as their response to a 
high-dose (250 μg) adrenocorticotropic hormone (ACTH) stimulation test. Subjects and methods: In 
27 patients with septic shock, baseline levels of aldosterone, cortisol, ACTH, renin, sodium, potassium, 
and lactate were measured, followed by a cortrosyn test. Results: Renin correlated with baseline 
aldosterone and its variation after cortrosyn stimulation. Baseline cortisol and its variation did not 
correlate with ACTH. Only three patients had concomitant dysfunction of aldosterone and cortisol 
secretion. Conclusions: Activation of the zona glomerulosa and zona fasciculata are independent. 
Aldosterone secretion is dependent on the integrity of the renin-angiotensin-aldosterone system, 
whereas cortisol secretion does not appear to depend predominantly on the hypothalamic-pituitary-
adrenal axis. These results suggest that activation of the adrenal gland in critically ill patients occurs 
by multiple mechanisms. Arq Bras Endocrinol Metab. 2013;57(8):636-41
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RESUMO 
Objetivo: Avaliar os níveis séricos dos principais fatores que regulam a ativação da zona glomeru-
losa e a produção de aldosterona em pacientes com choque séptico, assim como sua resposta ao 
teste de cortrosina em alta dose (250 µg). Sujeitos e métodos: Em 27 portadores de choque séptico, 
foram aferidos níveis basais de aldosterona, cortisol, ACTH, renina, sódio, potássio e lactato, bem 
como realizado teste de cortrosina. Resultados: Renina se correlacionou com níveis basais de aldos-
terona e sua variação após teste de cortrosina. Cortisol basal e sua variação não se correlacionaram 
com ACTH. Apenas três pacientes apresentaram disfunção concomitante da secreção de aldosterona 
e cortisol. Conclusões: Ativação das zonas fasciculada e glomerulosa são independentes. Secreção 
de aldosterona é dependente da integridade do sistema renina-angiotensina-aldosterona, enquanto 
secreção de cortisol não parece predominantemente dependente do eixo hipotálamo-hipófise-adre-
nal. Esses resultados sugerem que a ativação da adrenal em pacientes críticos ocorre por múltiplos 
mecanismos. Arq Bras Endocrinol Metab. 2013;57(8):636-41
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I n 1936, Hans Selye described the so-called “coun-tershock” response in experimental animals sub-
jected to electric shocks, characterized by adrenal gland 
swelling, atrophy of the thymus and lymphoid tissues, 
hyperchloremia and hypernatremia, increased blood 
volume, and increased diuresis. Selye also demonstrat-
ed that adrenalectomized animals were incapable of 
mounting such a response, thus establishing the asso-
ciation between stress and elevated cortisol levels. Se-
lye’s work and other studies set the foundation for the 
routine use of corticosteroid therapy in patients with 
septic shock, which persisted until the 1990s, when me-
ta-analyses showed that the way in which steroids were 
used in this setting (late administration of high doses) 
was not beneficial (1,2). Later knowledge has shown 
that stressful situations, such as septic shock, activate 
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quently triggering increases in cortisol levels. Patients 
who are unable to activate this axis exhibit higher mor-
tality rates (3,4). This dysfunction was originally known 
as relative adrenal insufficiency (RAI) (5), an outdated 
term that has been often replaced with critical illness-
related corticosteroid insufficiency (CIRCI) (6). Inter-
est in steroid treatment of patients with septic shock 
resurfaced in the early 2000s after some trials showed 
hemodynamic benefits and a possible reduction in mor-
tality with the early use of stress doses of hydrocortisone 
(200 mg/day) (7-9). Despite the substantial number of 
publications on the subject, questions remain as to the 
diagnosis of adrenal dysfunction in critically ill patients.
Most studies in critically ill patients have only as-
sessed the function of the zona fasciculata, the site of 
glucocorticoid production, even though glucocorti-
coids are predominantly anti-inflammatory and the 
main disturbances observed in clinical illness are po-
tentially attributable to mineralocorticoid action (va-
sopressor unresponsive hypotension, acidosis, and hy-
perkalemia). Furthermore, the main indications for and 
benefits of hydrocortisone in septic shock appear to be 
dependent on its mineralocorticoid effects.
Within this context, a better understanding of the 
activation mechanism of the zona glomerulosa in criti-
cally ill patients is imperative. This layer of the adre-
nal gland is the site of mineralocorticoid production, 
particularly aldosterone, which plays several vital roles 
in the setting of septic shock, such as sodium (and, 
consequently, fluid) retention and hypertensive effects, 
both of which are important for the maintenance of tis-
sue perfusion. Some studies have shown that critically 
ill patients are unable to increase aldosterone output 
during septic shock, and that this phenomenon occurs 
secondary to a blunted adrenal response to increased 
levels of renin, secreted by the juxtaglomerular appara-
tus. In critically ill patients, this dysfunction is known 
as hyperreninemic hypoaldosteronism (HH) (10). In 
other words, critically ill patients would exhibit lower 
aldosterone levels due to reduced production and/or 
secretion of aldosterone by the adrenal glands, as oc-
curs with the zona fasciculata and cortisol levels. In-
sufficient cortisol or aldosterone levels might lead to a 
major reduction in the activation of mineralocorticoid 
receptors, consequently leading to circulatory failure.
These aspects highlight the importance of research 
aimed at assessing the response of aldosterone to a va-
riety of stimuli in critically ill patients. Therefore, this 
study aimed to assess serum levels of the main factors 
that regulate the activation of the zona glomerulosa and 
aldosterone production in patients with septic shock, as 
well as their response to a high-dose (250 μg) adreno-
corticotropic hormone (ACTH) stimulation test.
SUBJECTS AND METHODS
This was a prospective study of 27 adult patients with 
septic shock admitted to the medical/surgical inten-
sive care unit (ICU) of Hospital de Clínicas de Por-
to Alegre, a tertiary care referral hospital in southern 
Brazil. The study was approved by the Research Ethics 
Committee of the institution and was conducted in ac-
cordance with the provisions of the Declaration of Hel-
sinki. Given the severity of the patients’ condition, writ-
ten informed consent was obtained from each patient’s 
closest relative prior to their inclusion in the study. 
Patients were eligible for the analysis if they were ≥ 
18 years of age and had a diagnosis of septic shock ac-
cording to the criteria of the American College of Chest 
Physicians/Society of Critical Care Medicine Confer-
ence Consensus Committee (11), requiring mechanical 
ventilation and use of vasoactive drugs despite adequate 
fluid replacement. Patients were recruited within 96 
hours of ICU admission. Exclusion criteria were as fol-
lows: history of chronic or acute use of exogenous cor-
ticosteroids; use of drugs that might interfere with adre-
nal function, such as etomidate, angiotensin-converting 
enzyme inhibitors, angiotensin II receptor antagonists, 
spironolactone, oral contraceptives, or antifungal agents; 
acquired immunodeficiency syndrome; history of adre-
nal insufficiency; HPA axis dysfunction; and pregnancy.
Baseline laboratory studies included blood sample 
collection for measurement of serum ACTH, renin, 
potassium, sodium, lactate, aldosterone, and total cor-
tisol levels. Immediately after baseline blood collection, 
patients underwent an ACTH stimulation test, which 
consisted of an intravenous injection of 250 μg tetraco-
sactide (Synacthen® 0.25 mg/1 mL; Novartis Pharma, 
Rueil-Malmaison, France), followed by measurement of 
aldosterone and cortisol levels at 30 and 60 minutes. All 
blood samples were obtained and drugs were injected 
through a central venous catheter. The change (Δ) in 
serum aldosterone and cortisol levels was determined by 
subtracting the baseline level from the peak level. Pa-
tients were classified as having CIRCI if basal cortisol 
was < 10 μg/dL or the variation in total cortisol levels 
(Δcortisol) after cortrosyn stimulation was < 9 μg/dL (6). 
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plasma renin activity ratio (Aldo/PRA) was < 2 and plas-
ma renin activity (PRA) was > 2 ng/mL/h (12). The 
decision to start corticosteroid therapy was made by the 
physician in charge outside the study, with no influence 
whatsoever from the investigators. Corticosteroids were 
always administered after the cortrosyn stimulation test 
and any other relevant therapeutic interventions.
Patients were followed up for 28 days after the cor-
trosyn stimulation test. Information was collected on 
age, sex, type of admission (medical or surgical), source 
of infection, Acute Physiology and Chronic Health 
Evaluation (APACHE) II score (13), duration of corti-
costeroid therapy, duration of vasoactive drug therapy, 
and outcome (death or survival) at 28 days. Time to 
withdrawal of vasoactive drugs was defined as successful 
weaning from vasopressor support for at least 24 hours.
ACTH levels were measured by chemiluminescence 
(Immulite 1000 Analyzer; Diagnostic Products Corp., 
Los Angeles, CA, USA), as were total serum cortisol 
levels (Modular E170 Analyzer; Roche Diagnostics, 
Mannheim, Germany). Aldosterone (reference range, 
2.94-16.15 ng/dL) and PRA (reference range, 0.51-
2.64 ng/mL/h) were measured by radioimmunoassay.
Statistical analysis 
Data were analyzed using the Statistical Package for 
the Social Sciences (SPSS) version 19.0 (SPSS Corp., 
Chicago, IL, USA). Normally distributed quantitative 
variables are expressed as mean ± standard deviation 
and asymmetrically distributed variables as median and 
interquartile range. The chi-square test was used for the 
assessment of categorical variables, and Student’s t test 
for continuous variables. The Spearman rank correla-
tion coefficient (rs) was used to test for the correlation 
between continuous variables, because of their non-
normal distribution. Survival analyses were performed 
using Kaplan-Meier curves. The log-rank test was used 
to compare survival curves and determine significant 
differences at different time points. The level of signifi-
cance was set at p < 0.05. To achieve a moderate corre-
lation between variables (correlation coefficient of 0.6), 
a significance level of 5% and a statistical power of 90%, 
a minimum sample size of 19 patients was required.
RESULTS
A total of 27 patients with septic shock were prospec-
tively recruited and included in the study sample. The 
demographic, clinical and laboratory characteristics of 
patients are described in table 1. Mean APACHE II 
score was 25.4, and 55.6% of patients died as a result 
of this condition (Table 1). Seven patients had PRA 
< 2 ng/mL/h and were therefore excluded from the 
analysis of Aldo/PRA, as aldosterone activity cannot be 
assessed at such low PRA levels (12). Particularly strik-
ing were the high mortality rate and disease severity 
(as expressed by high APACHE II scores) observed in 
our sample, which were nonetheless consistent with the 
Brazilian literature (14). Correlations between the main 
hormonal variables analyzed are shown in figure 1. A 
correlation was detected between PRA and baseline al-
dosterone levels (rs = 0.66, p < 0.05) and between PRA 
and change in aldosterone levels after cortrosyn stimula-
tion (rs = 0.42, p < 0.05). There was no correlation be-
tween PRA and levels of ACTH (rs = 0.065, p > 0.05), 
potassium (rs = 0.065, p > 0.05), or sodium (rs = -0.36, 
p > 0.05). Conversely, baseline aldosterone and cortisol 
levels were correlated (rs = 0.45, p < 0.05). The correla-
tion between baseline aldosterone and change in aldo-
sterone levels after stimulation did not reach statistical 
significance (rs = 0.367, p = 0.078). ACTH did not cor-
relate with baseline cortisol (rs = 0.07, p > 0.05), change 
in cortisol levels (rs = -0.36, p > 0.05), or aldosterone (rs 
= -0.17, p > 0.05). Likewise, baseline cortisol did not 
correlate with change in cortisol levels (rs = -0.057, p > 
0.05). There were no correlations between potassium, 
sodium, or lactate and baseline aldosterone or change 
in aldosterone levels after the cortrosyn stimulation test.
Of 20 patients with PRA > 2 ng/mL/h, eight had 
HH (40%), whereas six had CIRCI (30%). Only three 
patients (15%) exhibited both disorders concurrently.
Both aldosterone and cortisol levels increased sig-
nificantly after cortrosyn stimulation (p < 0.05), with 
aldosterone reaching peak levels at 60 minutes in 17 
patients (63%), and cortisol, in 25 patients (92.6%).
Limiting the analysis to non-dialysis patients at the 
time of hormone measurements did not change the 
correlation coefficient between the hormonal variables 
analyzed. Among these patients, there was an inverse 
relationship between sodium and potassium (rs = -0.79, 
p < 0.05). Mean sodium and potassium concentration 
among dialysis patients was not statistically different 
from that of non-dialysis patients (sodium, 142 ± 6.14 
mmol/L; potassium, 4.01 ± 0.75 mmol/L).
The probability of death at 28 days was 72.7% for 
patients with HH vs. 44.1% for patients without HH, 
and 43% for patients with CIRCI vs. 58% for patients 
without CIRCI. These differences were not statistically 
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Table 1. Characteristics of patients (n = 27)
Results























Blood glucose (mg/dL) 137 ± 39.4
ACTH (pg/mL) 22.4 (15.4 – 36.4)
Cortisol, baseline (μg/dL) 27.9 (21.9 – 38.4) 
Cortisol Δ (μg/dL) 16.4 (9.8 – 21.3)
PRA (ng/mL/h) 5.4 (2.16 – 15.6)
Aldosterone, baseline (ng/dL) 16.3 (10.7 – 29.1)
AldosteroneΔ (ng/dL) 6.9 (3.6 – 16.8)
Aldosterone/PRA 2.22 (1.2 – 3.4)
K+ (mmol/L) 4.2 ± 0.64
Na+ (mmol/L) 145 ± 6.5
Lactate (mmol/L) 2.2 (1.6 – 5.3)
Duration of corticosteroid therapy (days) 5.0 (1.0 – 9.0)
Duration of vasoactive drug therapy (days) 5.0 (2.0 – 6.0)
Mortality 15 (55.6%)
Results are expressed as n (%), mean ± standard deviation, or median and interquartile range.
APACHE: Acute Physiology and Chronic Health Evaluation; ACTH: adrenocorticotropic hormone; 




 = 0.66; p < 0.05
r
s 


























= 0.45; p < 0.05
1.C: Cortisol/aldosterone
0
0 20 40 60 80 100 120
Aldosterone












This study evaluated adrenal activation in the setting 
of septic shock in an attempt to contribute to further 
elucidation of the pathogenesis of adrenal dysfunction 
in this population by investigating both the zona fas-
ciculata and the zona glomerulosa of the adrenal gland. 
In our sample, PRA was the main determinant of se-
rum aldosterone levels (both at baseline and after cor-
trosyn stimulation) during shock. This finding, along 
with the lack of correlation between serum potassium, 
sodium or ACTH and aldosterone levels, suggests that 
hypotension and hypovolemia, which act as a major 
stimulus for renin release, are the main drivers of aldo-
sterone secretion in patients with septic shock. There-
fore, maintenance of the renin-angiotensin system ap-
pears to be essential for proper aldosterone production 
in the critically ill. These findings are consistent with 
data from a previous study by Cheyron and cols. (15), 
which was conducted in a population of critically ill pa-
tients with cirrhosis. 
Lactate, a marker of tissue perfusion and adrenergic 
status, was not a predictor of PRA in this study. The 
current literature suggests that, in the zona fasciculata, 
inflammatory mediators, such as interleukins and tu-
mor necrosis factor, may be more decisive determinants 
of basal cortisol and increases in cortisol levels (what 
some researchers term the “adrenal reserve”) than 
ACTH-mediated stimulation by the pituitary gland 
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2B: Mortality according to dysfunction in the adrenal zona fasciculate
HH: hyperreninemic hypoaldosteronism; 
CIRCI: critical illness-related corticosteroid insufciency.
0,2
0,0
0 5 10 15 20 25
Figure 2. Kaplan-Meier survival curves – Analysis of mortality at 28 days 
according to adrenal dysfunction.
(16). This assertion is, at least in part, supported by our 
results, which demonstrated no correlation between 
ACTH and baseline cortisol. Furthermore, in this 
study, in the setting of septic shock, there was no asso-
ciation between pituitary activity – a determining factor 
in ACTH release – and activation of the adrenal zona 
glomerulosa, as evidenced by the lack of association be-
tween ACTH and aldosterone levels. Also, there was 
no correlation between sodium or potassium levels and 
aldosterone secretion. This finding may be explained by 
the narrow range of variation in electrolyte levels de-
tected in the sample, which, in turn, may be explained 
by intensive control of fluid and electrolyte balance in 
the ICU and also by the fact that 37% of subjects were 
on dialysis treatment at the time of hormone measure-
ments. These factors prevented extreme levels of serum 
sodium and potassium and may, therefore, explain the 
lack of correlation between these levels and stimulation 
of the renin-angiotensin-aldosterone system (RAAS). 
Severe renal impairment may also have contributed to 
the low renin levels observed in this sample.
Our findings provide in vivo evidence that increases 
in aldosterone and cortisol secretion result from indepen-
dent mechanisms. This is consistent with previous studies 
involving critically ill patients with (17) or wi thout (18) 
sepsis. Therefore, patients with septic shock may exhibit 
insufficient glucocorticoid production without concomi-
tant deficiency of mineralocorticoid synthesis, and vice 
versa. Hypothetically, this dissociation may influence 
how steroids are replaced in septic patients. Patients with 
septic shock and mineralocorticoid dysfunction would 
benefit most from replacement therapy involving agents 
with mineralocorticoid activity, such as fludrocortisone 
or hydrocortisone, whereas patients with glucocorticoid 
dysfunction might benefit most from replacement with 
predominantly glucocorticoid agents, such as methyl-
prednisolone or dexamethasone. Accurate identification 
of these dysfunctions, together with determination of 
11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 
and 2 enzyme activity in order to detect greater sensi-
tivity of glucocorticoid or mineralocorticoid receptors, 
could contribute to the development of protocols for use 
of certain steroid agents in specific situations aiming to 
improve the inflammatory and circulatory responses. 
Our findings also give rise to a debate on how pa-
tients with these dysfunctions should be classified. 
The current literature suggests that the term “relative 
adrenal insufficiency” (RAI) should be replaced with 
“critical illness-related corticosteroid insufficiency” 
(CIRCI). However, our findings suggest that RAI and 
CIRCI should not be used interchangeably, as the zona 
fasciculate and the zona glomerulosa are activated in-
dependently. Dysfunction in aldosterone production at 
the zona glomerulosa was first identified in the 1980s 
and termed “hyperreninemic hypoaldosteronism” 
(HH) in the critically ill (10). Previous studies suggest 
that HH may be associated with increased mortality in 
these patients (15,19). Over the past 20 years, many 
studies have focused on cortisol production in septic 
patients, with particular emphasis on the definition of 
CIRCI and hydrocortisone replacement therapy. How-
ever, it is worth noting that the hypertensive effects 
of hydrocortisone are primarily due to its mineralo-
corticoid activity. Therefore, the potential benefits of 
hydrocortisone therapy to septic shock might not be 
observed in all patients, but perhaps only in those with 
aldosterone deficiency (HH). This hypothesis has yet 
to be evaluated in a randomized clinical trial.
In the present study, significant increases in aldoste-
rone and cortisol production occurred after stimulation 
with 250 μg cortrosyn, which suggests preservation of 
adequate adrenal reserve despite the lack of correlation 
between ACTH and variation in the level of these hor-
mones. This may have been due to high-intensity stim-
ulation by the high-dose cortrosyn test, which is often 
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many times greater than that observed during septic 
shock. Previous studies that found no increases in al-
dosterone production after an ACTH stimulation test 
concluded that dysfunction of the zona glomerulosa is 
not associated with circulating factors, including the 
RAAS. Unlike Raff and cols. (18), who assessed varia-
tion in aldosterone levels only 30 minutes after stimula-
tion, in the present study we assessed variation at 30 
and 60 minutes; within this timeframe, 63% of patients 
exhibited a peak aldosterone concentration. Therefore, 
these findings suggest that the RAAS continues to act 
as a determining factor in the activation of the zona 
glomerulosa even in the presence of sepsis, as observed 
in other pathological settings.
A limitation of this study is that we did not interfere 
with the therapeutic measures prescribed by attending 
physicians. Therefore, 25 patients (93%) received cor-
ticosteroids, although they were always administered 
after measurement of hormone levels. Thus, use of cor-
ticosteroid therapy and the small sample size prevented 
us from assessing clinical outcomes, such as mortality 
and duration of vasopressor support. Nevertheless, our 
results are consistent with trials suggesting that HH, 
detected by Aldo/PRA<2, is associated with increased 
mortality in critically ill patients, representing a po-
tential therapeutic target (10,12,15,17,19). We be-
lieve that further prospective trials designed to define 
whether HH and its clinical management correlate with 
improvement in clinical outcomes are still required.
The findings reported herein suggest that activation 
of the RAAS by hypotension, hypovolemia or other fac-
tors is the main determinant of aldosterone secretion 
in critically ill patients. ACTH, potassium and sodium 
levels do not appear to play a defining role in the main-
tenance and production of aldosterone in the adrenal 
zona glomerulosa in patients with septic shock. Fur-
thermore, this study showed that dysfunction in cortisol 
production (CIRCI) is not associated with dysfunction 
in aldosterone production (HH) in the zona glomeru-
losa. These findings may contribute to the development 
of new definitions for adrenal dysfunction in critically ill 
patients. Also, randomized clinical trials involving sever-
al different steroids – with predominant glucocorticoid 
or mineralocorticoid activity – in patients with more 
clearly defined adrenal disturbances are warranted.
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